clinical trial · NCT07834515
Phase 1b Clinical Study in Patients With Active Ulcerative Colitis
Ulcerative Colitis (UC)TP317Matching placebo
brief summary
Purpose of study is to evaluate the safety, tolerability, pharmacokinetics of TP317 vs. placebo in adults with active ulcerative colitis. Participants will be randomly assigned to receive either daily oral tablets (8 tablets) of TP317 (80 mg) or an identical placebo pill. Study will include 2 colonoscopies, daily dosing (including at home and in clinic), safety assessments, diary and questionnaire completion and 5 in clinic visits.
started
Sep 16, 2026
primary completion
Jul 29, 2027
completion
Aug 29, 2027
last updated
Sep 22, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy Signal of TP-317 in Patients With Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol